Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $20.69, up 3.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The CPRX shares have gain 5.62% over the last week, with a monthly amount glided 21.71%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on March 14, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $27. Previously, BofA Securities started tracking the stock with Buy rating on March 07, 2024, and set its price target to $23. On December 21, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $30 on the stock. ROTH Capital downgraded its rating to a Neutral and increased its price target to $15.50 on August 24, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight. In a note dated October 05, 2016, Piper Jaffray upgraded an Overweight rating on this stock.
Catalyst Pharmaceuticals Inc [CPRX] stock has fluctuated between $11.55 and $20.31 over the past year. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $20.69 at the most recent close of the market. An investor can expect a potential drop of -6.33% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 434.48M for the trailing twelve months, which represents a growth of 23.23%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.14 and Total Capital is 0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.19 points at the first support level, and at 19.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.96, and for the 2nd resistance point, it is at 21.22.
Ratios To Look Out For
For context, Catalyst Pharmaceuticals Inc’s Current Ratio is 5.14. On the other hand, the Quick Ratio is 4.94, and the Cash Ratio is 4.07. Considering the valuation of this stock, the price to sales ratio is 5.65, the price to book ratio is 4.03 and price to earnings (TTM) ratio is 38.78.
Transactions by insiders
Recent insider trading involved Miller Steve, Officer, that happened on Aug 20 ’24 when 0.15 million shares were purchased. Chief Commercial Officer, Del Carmen Jeffrey completed a deal on Aug 09 ’24 to sell 36058.0 shares. Meanwhile, Chief Med. & Reg. Officer INGENITO GARY sold 100000.0 shares on Aug 09 ’24.
